Former India opener Gautam Gambhir says if the IPL is not played this year, it will be difficult for Mahendra Singh Dhoni to make a comeback to the Indian team.
Dhoni last played for India in the World Cup semifinal against New Zealand in July last year.
Since then he hasn't played any competitive cricket and legends such as Sunil Gavaskar and Kapil Dev have already said that it's getting increasingly difficult for the Jharkhand dasher to make an international return after such a prolonged sabbatical.
He was expected to be seen in action at this year's IPL but the chances of T20 league being played are remote due to the COVID-19.
"If the IPL does not happen this year, then it will become very difficult for MS Dhoni to make a comeback. On what basis can he (Dhoni) be selected since he's not been playing for the last one or one and a half year," Gambhir said on Star Sports show Cricket Connected.
The 38-year-old Gambhir picked KL Rahul, who has been keeping in ODIs, as an "apt replacement" for Dhoni.
"Obviously his (Rahul's) keeping is not as good as Dhoni's, but if you are looking at T20 cricket, Rahul's a utility player, can keep and bat at No. 3 or 4. If the IPL does not happen, then Dhoni's chances for a comeback look dim.
"Ultimately, you are representing India, so whoever dishes out the best performance and can win the match for India should play for the team," added Gambhir.
Gambhir also felt that retirement was Dhoni's personal decision.
"As far as his retirement plans go by, that's his personal choice," said Gambhir.
However, his former teammate and test specialist VVS Laxman feels that Dhoni can continue playing IPL.
"Not only this IPL, he (Dhoni) will probably play in the next couple of IPLs, and then we will take a call about his future as a cricketer," Laxman said on the same show.
However, Laxman, a veteran of 134 Tests, said that the new selection committee, chaired by former spinner Sunil Joshi, will have to discuss Dhoni's future with him.
"Dhoni will be very clear, as far as his plans are concerned. I'm sure he must have communicated that with (captain) Virat Kohli, (coach) Ravi Shastri immediately after the 2019 World Cup in England," said Laxman.
"The new selection committee will have to sit down with MS Dhoni and understand his future, as far as Indian cricket is concerned. But MS Dhoni will continue to play for CSK and do well for CSK," said Laxman, who amassed 8,781 Test runs.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.